Clinical trial of the oral administration of OK-432 to the patients with oral cancer(the first report). Measuring of the specific IgA for OK-432 in saliva.:Measuring of the specific IgA fbr OK-432 in saliva

スポンサーリンク

概要

• 論文の詳細を見る

• OK-432 is generally given muscularly or subcutaneously. But, in the case of the subcutaneous injection, one often cannot help ceasing to inject because of severe local dermal reaction. The local immunity at the intestinum mucosa suggested by Besredka in 1927, was applied to the oral administration. McGhee reported that antigen given perorally stimulates the immuno competent cell at Peyer's nodules. The stimulated immuno competent cell becomes matured by general circulation and reaches the local mucosa of salivary glands and guts etc, and then produces the specific IgA. The eight cases, administered perorally, were followed. Three were tongue, two were mandibul and maxilla and one was floor of the mouth. Six subjects were males, two were females. Radiotherapy was given in all cases, operations in five cases. The usual dose of OK-432 was 5 KE. It was administered for seven consecutive days and during about two months administered every other day, after that once a week or two. The immune reactions of the skin test for Su-PS and PPD were examined before administration and one, two, and four weeks, two and three moths after. At the same time the specific IgA for OK-432 in saliva was also examined. The levels of the s-IgA tended to increase after oral administration. In cases of increasing levels of s-IgA, the reactions of thes kin test for Su-PS were enhanced. This suggested the possibility of the oral administration of OK-432 stimulating general immunity.<BR>Now, the levels of the s-IgA were correlated with the reactions of the skin test for Su-PS. So we will be able to interpret the general immunity from the reactions of the skin test for Su-PS. The relation between the reactions of the skin test for PPD and the levels of the s-IgA were not defined.

• 社団法人 日本口腔外科学会の論文

著者

• 北山 誠二

  名古屋第一赤十字病院歯科口腔外科

• 長尾 徹

  名古屋第一赤十字病院歯科口腔外科

• 柴田 芳孝

  名古屋第一赤十字病院歯科口腔外科

• 豊田 哲郎

  名古屋第一赤十字病院歯科口腔外科

• 近藤 和彦

  名古屋第一赤十字病院歯科口腔外科

関連論文

• 歯科・口腔外科領域における炎症性疾患に対するエモルファゾンの臨床評価 : アスピリンとの二重盲検比較試験
• エモルファゾンの歯科・口腔外科領域における炎症性疾患に対する効果 : 一般臨床試験
• 下唇癌が下顎神経を経て進展した1例
• 下顎骨切除後の大耳介神経移植の経験
• 骨髄移植後の慢性 Graft-versus-host-disease (GVHD) の口腔内症状
• 頬骨弓単独骨折に対する固定法の1工夫
• 下顎頭骨折整復の1工夫
• Hotz 型人工口蓋床による口唇口蓋裂早期治療 : 第3報 Pierre Robin 症候群への応用と早期治療
• Clinical study of a combination chemotherapy with Peplomycin, Cisplatin and Mitomycin C (PPM therapy) for advanced and recurrent carcinoma of the head and neck : Report of seven cases.
• A modification of hard palate compression for marked atrophic maxilla.
• A modification of the Bernard cheiloplasty for carcinoma of the lower lip.
• Study on transmigration of Cefotetan in oral tissues.
• Bifid tongue: Report of a case
• Ameloblastoma of the maxilla : Report of a case.
• 耳下腺腫瘍を疑わしめた下顎放線菌症の1例
• 顎関節突起骨折の遠隔成績について-X線写真での治癒状態と臨床予後-
• Clinical trial of the oral administration of OK-432 to the patients with oral cancer(the first report). Measuring of the specific IgA for OK-432 in saliva.:Measuring of the specific IgA fbr OK-432 in saliva

もっと見る 閉じる

スポンサーリンク